Grindeks launches antiviral medication Rimantadine-Grindeks

Grindeks launches antiviral medication Rimantadine-Grindeks

12/11/2009

Joint Stock Company Grindeks informs on launching of Rimantadine-Grindeks 50mg - the effective and recognized antiviral medication for treatment of seasonal flu. After the receiving of registration approval from the State Agency of Medicines, Grindeks will start to manufacture this medicine and promises that Rimantadine-Grindeks 50mg will be available at the local pharmacies in nearest months.

The active substance of Rimantadine-Grindeks is rimantadine hydrochloride and its commonly used chemical name is rimantadine. For the first time the substance was synthesized in Latvian Institute of Organic Synthesis 40 years ago.

Chairman of the Board of Grindeks Jānis Romanovskis: “In response to expansion of pandemic influenza in Latvia, we will offer Rimantadine-Grindeks – effective and recognized antiviral medication for treatment of seasonal flu. According to the data of World Health Organization (WHO), so called “swine flu” will be acute until the new year and will prevail over the seasonal flu, which in turn will be acute in the new year. I am pleased that Rimantadine-Grindeks will help Latvian society to fight against the flu and to recover!”

Grindeks plans to register and manufacture also Rimantadine-Grindeks 100mg.

According to the “WHO Guidelines for Pharmacological Management of Pandemic 2009 Influenza and other Influenza Viruses”, published on 20 August 2009, rimantadine has been acknowledged as efficient antiviral medication.

About Grindeks

Grindeks is the leading pharmaceutical company in the Baltic States. The main directions of its operation are research, development, manufacturing and sales of original products, as well as generics and active pharmaceutical ingredients. Grindeks concern consists of four subsidiary companies in Latvia, Estonia and Russia; as well as representatives and representative offices in 14 countries. Products of the company are exported to more than 40 countries and its export comprises more than 96% of the total turnover. The main markets are the Baltic States, Russia and other CIS countries, as well as Japan and USA. The shares of JSC Grindeks are listed in the Official List of “Nasdaq OMX Riga”.

Further information:

Laila Kļaviņa
Head of the Communications Department
JSC Grindeks
E-mail: [email protected]
Phones: +371 67083370, +371 29256012

Related posts

JSC Grindeks audited financial results for twelve months of 2014

Today, on 30 April, the JSC Grindeks submitted the audited consolidated financial statements for twelve months of 2014 to “Nasdaq Riga”. Audited financial results indicate that the Group closed 2014 with a net loss of 2.5 million euros related to the shareholders of the holding company. In comparison the Group’s net profit in 2013 was […]
30/04/2015
evidence-that-meldonium-enhances

Experts: There’s no evidence that meldonium enhances performance

There’s really no evidence that there’s any performance enhancement from meldonium, said Don Catlin, a long-time anti-doping expert and the scientific director of the Banned Substances Control Group. Those questions highlight a difficult position for WADA, With scant existing research, how does it know meldonium enhances performance? Does it need to ban a drug like […]
08/04/2016
backgroundImg4

JSC Grindeks receives Gold in “Trade Mark 2018” competition in Ukraine

In the annual Ukrainian competition “Trade Mark 2018” („Фавориты Успеха”) JSC Grindeks product Viprosal B®* has received Golden Award in “Muscle and Joint Pain Treatment” category. All products and services trade marks represented in the Ukrainian market were included in the competition and divided in corresponding products and services categories. Three respondent groups – expert […]
28/05/2019
magnifiercrossmenu